Share |

Content about manufacturing

January 30, 2012

McCormick & Company, Incorporated (NYSE: MKC) was founded in 1889 and is the global leader in the manufacturing, marketing and distribution of spices, seasonings and flavorings to the entire food industry. It has its headquarters near Baltimore, Maryland. The company reported earnings on January 26, 2012, beat slightly on revenues and met expectations on earnings per share for the fourth quarter.

February 21, 2014

The Baltimore/Washington International Thurgood Marshall Airport had a total of 22,498,353 commercial passengers flow through its gates in 2013 making it – once again – the busiest airport in the Washington, D.C. area.

February 19, 2014

Fulton, Maryland-based Colfax Corporation (NYSE:CFX) has made another large acquisition; less than three years after purchasing Charter International PLC in September 2011 for $2.4 billion.

May 29, 2012

Fulton, Maryland-based Colfax Corporation (NYSE: CFX), has taken interest in another foreign mechanical technology supplier after the acquisition of Charter international which has propelled the companies quarterly revenues to figures approaching $1 billion.

The manufacturing and engineering company said it would pay $235 million for Soldex S.A, a welding products supplier based in the South American country of Peru. Soldex has manufacturing plants in Lima, Peru and Bogota, Colombia.

December 7, 2011

Fulton, Maryland-based Colfax Corporation (NYSE: CFX), has announced that it has purchased a national supplier of oil flushing and remediation services for $34 million.

COT-PURITECHwith current headquarters in Canton, Ohio reported $20 million in annual revenues last year by supplying its products to refinery and petrochemical operators, power generation plants and other industrial manufacturing sites according to the release.

August 16, 2011

PharmAthene, Inc. (AMEX: PIP), an Annapolis based biodefense company, announced that they have been awarded $5.7 million by the Department of Defense (DoD) to continue research of its nerve agent medical countermeasure program.

The contract will allow PharmAthene to evaluate mammalian cell-based manufacturing system for rBChE for a period of 18 months. The company indicated that if the research is successful, it could increase production, flexibility, and be cost-effective.